Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant ...
Tag: melanoma
Adjuvant dabrafenib and trametinib improve survival in stage III melanoma
1. After almost 10 years of follow-up, adjuvant dabrafenib and trametinib improved relapse-free and metastasis-free survival compared to placebo in ...
BioNTech’s mRNA Cancer Candidate Packs A Punch With Regeneron’s Cemiplimab In Phase 2 Melanoma Trial
Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or advanced-stage anti-PD-1 refractory melanoma ...
#VisualAbstract: Adjuvant Pembrolizumab Shows Similar Outcomes to Placebo in Resected Stage III Melanoma
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Adjuvant Dabrafenib plus Trametinib Improves Outcomes in Stage III Melanoma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Long-term survival improved with use of tebentafusp for metastatic uveal melanoma
1. Across a median follow-up of 48.5 months, usage of tebentafusp for patients with metastatic uveal melanoma was associated with ...
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
1. The event-free survival at 12 months was 83.7% in the neoadjuvant group vs 57.2% in the adjuvant group. 2. ...
Neoadjuvant Dual vs Single Checkpoint Inhibitors in High-Risk Melanoma
1. The pathological response rate had an OR of 3.16 when comparing neoadjuvant dual vs single checkpoint inhibitors. 2. The ...
Individualized cancer mRNA-based cancer therapy shows benefit in patients with high-risk melanoma on immunotherapy
1. 18-month recurrence-free survival was significantly greater in the combination therapy group compared to pembrolizumab alone. 2. There were no ...